Triad Healthcare Partners

M&A Licensing for Pharmaceutical and Medical Device Companies

a division of Triad Securities Corp.

Provides investment banking services to pharmaceutical and medical device companies on a global basis

Andrew Hirchberg and Mark Palmer work with global clients

Providing strategic advisory services related to all aspects of mergers, acquisitions and licensing activities

Andrew Hirschberg

Has been advising clients for 30 years and has completed over 100 transactions in multiple specialties (dermatology, gastroenterology, pediatrics, nephrology, etc.) with an aggregate value exceeding $5 billion.

Mark Palmer

Led business development for two specialty pharmaceutical companies (Braintree Laboratories, Inc. and Medicis Pharmaceutical Corp.) for the 10 years prior to joining Triad Healthcare Partners. During that time, Mark led and completed transactions with an aggregate value of well over $1 billion . These transactions were primarily in dermatology, gastroenterology, orphan drugs and pediatrics.

vast healthcare-experience in sourcing deals

and representing clients in all aspects of deal making and negotiation in the global specialty pharmaceutical and medical device sectors

Prior to forming Triad Healthcare Partners , Andrew and Mark worked together as investment bankers at another broker-dealer, where they advised clients on strategic transactions and completed multiple M&A and licensing deals.

Andrew and Mark work with companies throughout the development and commercialization timeline and assist with in/out-licensing and mergers and acquisitions to maximize value for the shareholders of client companies.

Mergers and Acquisitions

Andrew Hirschberg
Head of Investment Banking
Triad Healthcare Partners
Mark Palmer
Managing Director
Triad Healthcare Partners

Representative Transactions

MedicisSale of CompanyValeantz$2.6 B
MerzPharmaCompany AcquisitionUltheraUp to $600M
Revision Skincare/ Goodier CosmeticsMajority Stake SoldRoundTable HealthcareUndisclosed
Novan, Inc.Out-license of SB204 (Phase 3, acne) for JapanSato Pharmaceutical Co.Up $42.4M + Royalties
Merz PharmaSale of Dermatology AssetsSebela PharmaceuticalsUndisclosed
Neocutis SASale of CompanyMerz PharmaUndisclosed
Brickell BiotechOut-license of hyperhidrosis asset (Phase 2) for Japan/other Asian countriesKaken PharmaceuticalUndisclosed
MedicisAcquisition of Company’s AssetsGraceway Pharmaceuticals$455 M
Precision DermatologyAcquisition of Clindagel AssetsGalderma LaboratoriesUndisclosed
Braintree LaboratoriesSale of PhosLo Product LineNabi Biopharmaceuticals$120 M
IvaxAcquisition of Nasarel and Nasalide Prod. LinesElan Corporation$140 M
Hill DermaceuticalsSale of Triluma Product LineGalderma Laboratories$100 M+
R&D LaboratoriesSale of CompanyWatson Pharmaceuticals$185 M
Braintree LaboratoriesOut-license of SuPrep For 50-countries (Ex-North America)Ipsen GroupUndisclosed
MedicisSale of Ascent PediatricsBioMarin Pharmaceutical$190 M
Ferndale LaboratoriesSale of Locoid Product LineTriax Pharmaceuticals$120 M
Daniels PharmaceuticalsSale of CompanyJones Medical Industries$130 M
Braintree LabratoriesSale of MiraLax OTC RightsSchering-PloughUndisclosed